UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - STEMLINE THERAPEUTICS INC ownership

Quarter-by-quarter ownership
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ownership history of STEMLINE THERAPEUTICS INC
ValueSharesWeighting
Q1 2020$188,358,000
-54.8%
38,917
-0.7%
0.00%
Q4 2019$416,803,000
+27.2%
39,210
+24.6%
0.00%
Q3 2019$327,551,000
+20.2%
31,465
+76.9%
0.00%
Q2 2019$272,497,000
+19.2%
17,7870.0%0.00%
Q1 2019$228,563,000
+12762.3%
17,787
+9411.8%
0.00%
Q4 2018$1,777,000
-42.8%
1870.0%0.00%
Q3 2018$3,104,000
+3.4%
1870.0%0.00%
Q2 2018$3,001,0001870.00%
Other shareholders
STEMLINE THERAPEUTICS INC shareholders Q2 2024
NameSharesValueWeighting ↓
QVT Financial LP 220,000$9,965,0000.68%
Healthcare Value Capital, LLC 16,464$746,0000.65%
EAM Investors, LLC 69,151$3,132,0000.62%
Baker Brothers Advisors 800,400$36,255,0000.52%
Spark Investment Management LLC 38,300$1,733,0000.40%
Perceptive Advisors 180,416$8,172,0000.34%
SIGMA CAPITAL MANAGEMENT LLC 175,000$7,926,0000.33%
DRIEHAUS CAPITAL MANAGEMENT LLC 129,915$5,885,0000.23%
Visium Asset Management, LP 150,000$6,794,0000.15%
ESSEX INVESTMENT MANAGEMENT CO LLC 19,732$894,0000.14%
View complete list of STEMLINE THERAPEUTICS INC shareholders